Cell therapy trial for Parkinson's Disease


Biotech group Living Cell Technologies plans to treat patients for Parkinson’s Disease using medical tourism, if its clinical trial under way in Auckland succeeds.

The phase 11b clinical trial of 18 patients is underway at Auckland City Hospital on its regenerative cell therapy NTCELL, which would be the world’s first disease-modifying treatment for Parkinson’s.

Results are expected mid-next year from the escalating dosage clinical trial being carried out in three legs and requires consent from the Data Safety Monitoring board at the end of each 26-week period after the cells are implanted.

If the second trial proves successful, the company will apply for provisional consent that would speed up approval for treatments for severe illnesses that speed up approval to treat paying patients in New Zealand next year, including patients brought in from other countries.




Do you have some news or a press release that you’d like to share with the medical travel industry?

Publish for FREE on IMTJ.


Related News

COVID-19 impact on US health insurance

22 May, 2020

20% unemployment in the USA will mean 37 million uninsured

Azerbaijan tourism reboot

18 May, 2020

Azerbaijan launches health and safety campaign

Indian hotels focus on hygiene

14 May, 2020

ITC Hotels launches initiative on safety, hygiene protocol

Global hotels promote cleanliness

07 May, 2020

Safety and cleanliness programmes for tourism

Malaysia tourism taskforce

07 May, 2020

Malaysian state Penang looks at tourism revival